Cyclophosphamide Treatment Options in Columbus, OH (Updated 7/25)

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

NCT04994132

Active Not Recruiting

This phase III trial compares the safety and effect of adding vinorelbine to vincristine, dactinomycin, and cyclophosphamide (VAC) for the treatment of patients with high risk rhabdomyosarcoma (RMS). High risk refers to cancer that is likely to recur (come back) after treatment or spread to other parts of the body. This study will also examine if adding maintenance therapy after VAC therapy, with or without vinorelbine, will help get rid of the cancer and/or lower the chance that the cancer come... Read More

Gender:

ALL

Ages:

50 years and below

Trial Updated:

07/10/2025

Locations: Children's Hospital Medical Center of Akron, Akron, Ohio +7 locations

Conditions: Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Solid Alveolar Rhabdomyosarcoma, Spindle Cell Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma, Metastatic Embryonal Rhabdomyosarcoma, Metastatic Rhabdomyosarcoma

Register for Updates

Learn More ›

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

NCT02724579

Active Not Recruiting

This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT)/Wingless (WNT)-driven medulloblastoma. Recent studies using chemotherapy and radiation therapy have been shown to be effective in treating patients with WNT-driven medulloblastoma. However, there is a concern about the late side effects of treatment, such as learning difficulties, lower amount... Read More

Gender:

ALL

Ages:

Between 3 years and 21 years

Trial Updated:

07/10/2025

Locations: Children's Hospital Medical Center of Akron, Akron, Ohio +6 locations

Conditions: Medulloblastoma

Register for Updates

Learn More ›

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

NCT06647953

Recruiting

This phase III trial tests how well surgery plus chemotherapy compared to surgery alone works in treating patients with type I pleuropulmonary blastoma (PPB), and tests how well surgery plus standard chemotherapy with the addition of topotecan works compared to surgery plus standard chemotherapy alone in treating patients with type II and III PPB. Historically, most children with type I PPB had surgery and approximately 40% of children with type I PPB received chemotherapy following their surge... Read More

This phase III trial tests how well surgery plus chemotherapy compared to surgery alone works in treating patients with type I pleuropulmonary blastoma (PPB), and tests how well surgery plus standard chemotherapy with the addition of topotecan works compared to surgery plus standard chemotherapy alone in treating patients with type II and III PPB. Historically, most children with type I PPB had surgery and approximately 40% of children with type I PPB received chemotherapy following their surgery, usually for 22-42 weeks. There has not been a consistent standard for which children with type I PPB receive chemotherapy after surgery. For patients whose tumor has been removed completely with surgery, observation without chemotherapy may work as well as giving chemotherapy after surgery in preventing a return of the PPB tumor. The standard chemotherapy for patients with types II or III PPB in the United States is four cycles of IVADo (ifosfamide, vincristine, dactinomycin, and doxorubicin) followed by 8 cycles of IVA (ifosfamide, vincristine and dactinomycin). Ifosfamide is in a class of medications called alkylating agents. It works by slowing or stopping the growth of tumor cells in the body. Vincristine is in a class of medications called vinca alkaloids. It works by stopping tumor cells from growing and dividing and may kill them. Dactinomycin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. Topotecan is in a class of medications called topoisomerase I inhibitors. It works by interfering with tumor cell DNA which kills them. Giving topotecan in addition to standard IVADo and IVA chemotherapy regimens may shrink the cancer as well as or better than the standard therapy or could decrease the chance the tumor spreads while causing fewer side effects. Read Less

Gender:

ALL

Ages:

21 years and below

Trial Updated:

07/10/2025

Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio +3 locations

Conditions: Pleuropulmonary Blastoma

Register for Updates

Learn More ›

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

NCT02981628

Recruiting

This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.

Gender:

ALL

Ages:

Between 1 year and 21 years

Trial Updated:

07/09/2025

Locations: Children's Hospital Medical Center of Akron, Akron, Ohio +5 locations

Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma

Register for Updates

Learn More ›

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

NCT03959085

Recruiting

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin.... Read More

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy. Read Less

Gender:

ALL

Ages:

Between 1 year and 25 years

Trial Updated:

07/09/2025

Locations: Children's Hospital Medical Center of Akron, Akron, Ohio +6 locations

Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia

Register for Updates

Learn More ›

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

NCT04322318

Recruiting

This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth... Read More

Gender:

ALL

Ages:

30 years and below

Trial Updated:

07/09/2025

Locations: Children's Hospital Medical Center of Akron, Akron, Ohio +6 locations

Conditions: Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor

Register for Updates

Learn More ›

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

NCT05304585

Recruiting

Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatment with 24 weeks of vincristine and dactinomycin (VA) and examines the use of centralized molecular risk stratification in the treatment of rhabdomyosarcoma. Another aim of the study it to find out how well patients with low risk rhabdomyosarcoma (LR-... Read More

Gender:

ALL

Ages:

21 years and below

Trial Updated:

07/09/2025

Locations: Children's Hospital Medical Center of Akron, Akron, Ohio +6 locations

Conditions: Embryonal Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma

Register for Updates

Learn More ›

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

NCT05999994

Recruiting

The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.

Gender:

ALL

Ages:

Between 1 year and 39 years

Trial Updated:

07/07/2025

Locations: Nationwide Children's Hosp, Columbus, Ohio

Conditions: Neoplasms, Child, Adolescent

Register for Updates

Learn More ›

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

NCT04139304

Recruiting

This feasibility trial studies how well daratumumab in combination with dose-adjusted etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (DA-EPOCH) works in treating patients with newly diagnosed stage I-IV plasmablastic lymphoma. Plasmablastic lymphoma cells have high levels of a protein called CD38. Daratumumab is a monoclonal antibody that specifically targets CD38 expressing cells, and may help the body's immune system attack the cancer and interfere... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/26/2025

Locations: The Ohio State University, Columbus, Ohio

Conditions: Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Plasmablastic Lymphoma

Register for Updates

Learn More ›

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

NCT01275677

Completed

This randomized phase III clinical trial studies chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving chemotherapy after surgery may kill more tumor cells. Monoclonal antibodies,... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/25/2025

Locations: Summa Health System - Akron Campus, Akron, Ohio +97 locations

Summa Health System - Akron Campus, Akron, Ohio

Summa Health System - Barberton Campus, Barberton, Ohio

Cleveland Clinic Cancer Center Beachwood, Beachwood, Ohio

UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio

Mary Rutan Hospital, Bellefontaine, Ohio

Strecker Cancer Center-Belpre, Belpre, Ohio

Toledo Clinic Cancer Centers-Bowling Green, Bowling Green, Ohio

Aultman Health Foundation, Canton, Ohio

Miami Valley Hospital South, Centerville, Ohio

Geauga Hospital, Chardon, Ohio

Adena Regional Medical Center, Chillicothe, Ohio

Oncology Hematology Care Inc-Eden Park, Cincinnati, Ohio

Oncology Hematology Care Inc-Mercy West, Cincinnati, Ohio

The Christ Hospital, Cincinnati, Ohio

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio

Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio

Oncology Hematology Care Inc-Anderson, Cincinnati, Ohio

Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio

Bethesda North Hospital, Cincinnati, Ohio

Oncology Hematology Care Inc-Blue Ash, Cincinnati, Ohio

TriHealth Cancer Institute-Westside, Cincinnati, Ohio

TriHealth Cancer Institute-Anderson, Cincinnati, Ohio

Case Western Reserve University, Cleveland, Ohio

MetroHealth Medical Center, Cleveland, Ohio

Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

North Coast Cancer Care-Clyde, Clyde, Ohio

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Mount Carmel East Hospital, Columbus, Ohio

Columbus Oncology and Hematology Associates Inc, Columbus, Ohio

Riverside Methodist Hospital, Columbus, Ohio

Columbus NCI Community Oncology Research Program, Columbus, Ohio

Grant Medical Center, Columbus, Ohio

The Mark H Zangmeister Center, Columbus, Ohio

Mount Carmel Health Center West, Columbus, Ohio

Doctors Hospital, Columbus, Ohio

Grandview Hospital, Dayton, Ohio

Good Samaritan Hospital - Dayton, Dayton, Ohio

Miami Valley Hospital, Dayton, Ohio

Miami Valley Hospital North, Dayton, Ohio

Dayton NCI Community Oncology Research Program, Dayton, Ohio

Delaware Health Center-Grady Cancer Center, Delaware, Ohio

Delaware Radiation Oncology, Delaware, Ohio

Grady Memorial Hospital, Delaware, Ohio

Hematology Oncology Center Incorporated, Elyria, Ohio

Mercy Cancer Center-Elyria, Elyria, Ohio

Oncology Hematology Care Inc-Healthplex, Fairfield, Ohio

Blanchard Valley Hospital, Findlay, Ohio

Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio

Wayne Hospital, Greenville, Ohio

Cleveland Clinic Cancer Center Independence, Independence, Ohio

Kettering Medical Center, Kettering, Ohio

Fairfield Medical Center, Lancaster, Ohio

Lancaster Radiation Oncology, Lancaster, Ohio

Saint Rita's Medical Center, Lima, Ohio

Lima Memorial Hospital, Lima, Ohio

OhioHealth Mansfield Hospital, Mansfield, Ohio

Cleveland Clinic Cancer Center Mansfield, Mansfield, Ohio

Marietta Memorial Hospital, Marietta, Ohio

Saint Luke's Hospital, Maumee, Ohio

Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio

Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio

Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio

UH Seidman Cancer Center at Landerbrook Health Center, Mayfield Heights, Ohio

UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio

UH Seidman Cancer Center at Southwest General Hospital, Middleburg Heights, Ohio

Knox Community Hospital, Mount Vernon, Ohio

Licking Memorial Hospital, Newark, Ohio

Newark Radiation Oncology, Newark, Ohio

Fisher-Titus Medical Center, Norwalk, Ohio

Saint Charles Hospital, Oregon, Ohio

Toledo Clinic Cancer Centers-Oregon, Oregon, Ohio

Southern Ohio Medical Center, Portsmouth, Ohio

North Coast Cancer Care, Sandusky, Ohio

UH Seidman Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio

Springfield Regional Medical Center, Springfield, Ohio

Trinity's Tony Teramana Cancer Center, Steubenville, Ohio

Cleveland Clinic Cancer Center Strongsville, Strongsville, Ohio

ProMedica Flower Hospital, Sylvania, Ohio

Mercy Hospital of Tiffin, Tiffin, Ohio

ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio

Mercy Health - Saint Vincent Hospital, Toledo, Ohio

University of Toledo, Toledo, Ohio

Toledo Community Hospital Oncology Program CCOP, Toledo, Ohio

Mercy Health - Saint Anne Hospital, Toledo, Ohio

Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio

Upper Valley Medical Center, Troy, Ohio

University Hospitals Sharon Health Center, Wadsworth, Ohio

South Pointe Hospital, Warrensville Heights, Ohio

Fulton County Health Center, Wauseon, Ohio

University of Cincinnati Cancer Center-West Chester, West Chester, Ohio

Saint Ann's Hospital, Westerville, Ohio

UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio

Clinton Memorial Hospital/Foster J Boyd Regional Cancer Center, Wilmington, Ohio

Cleveland Clinic Wooster Family Health and Surgery Center, Wooster, Ohio

Wright-Patterson Medical Center, Wright-Patterson Air Force Base, Ohio

Greene Memorial Hospital, Xenia, Ohio

Genesis Healthcare System Cancer Care Center, Zanesville, Ohio

Conditions: HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7

Register for Updates

Learn More ›

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

NCT03150693

Suspended

This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal antibodies, such as inotuzumab ozogamicin, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or... Read More

Gender:

ALL

Ages:

Between 18 years and 39 years

Trial Updated:

06/24/2025

Locations: University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio +4 locations

Conditions: B Acute Lymphoblastic Leukemia

Register for Updates

Learn More ›

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

NCT04803201

Recruiting

This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/24/2025

Locations: Miami Valley Hospital South, Centerville, Ohio +14 locations

Conditions: Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified

Register for Updates

Learn More ›

Cyclophosphamide Treatment Options in Columbus, OH

Match to Clinical Trials

Browse Cyclophosphamide Treatment Options in Other Ohio Cities